CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
CCTG is pleased to announce the agenda for the Plenary Session at the #CCTG2026 Spring Meeting.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting
The Investigational New Drug Program Team Award was presented to the IND.244 team at CHU de Québec – Hôpital L’Enfant-Jésus for their work activating and recruiting patients to this trial. Awarded at the CCTG Spring Meeting to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in a CCTG IND clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
The Ralph Meyer Phase III Program Young Investigator Award has been awarded to Dr. Rachel Glicksman from Princess Margaret Cancer Centre recognizing her active participation and enrollment activities as a young investigation in CCTG trials. This award is presented to individuals who have made significant contributions to the phase III program research projects.
It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year.
Congratulations to Dr. Moira Rushton, a Medical Oncologist from the Ottawa Hospital Research Institute who has been awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for her work on CCTG IND trials and committees.
“I am truly honored to have been selected as the recipient of this year’s Elizabeth Eisenhauer early drug development young investigator award. My time at CCTG was an invaluable formative experience and continues to meaningfully impact my clinical practice and academic career,” says Dr Rushton.
Congratulations to the PR.24 trial team from Odette Cancer Centre who were presented the Phase III Program Team Award at the 2025 Spring Meeting for their work and dedication to this CCTG led prostate cancer trial. This recognition is awarded to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in this phase III clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
CCTG was pleased to present the Excellence in Clinical Trials Conduct award to Iryna Sokolenko at North York General Hospital for her work to support our trials and contributions to patient-focused research. Iryna is the PCRA for CRC.10 and has been recognized as having exceptional attention to detail who's genuine care made participating in the trial a positive experience for patients. This is presented annually to an individual who exemplifies excellence in clinical trial operations and compliance at their institution.
CCTG will be holding the next CRA Lunch and Learn on Wednesday June 11th, 2025, at 12 pm ET. Session 5 will cover the topic of Understanding the Centre Performance Index (CPI)
